Register Login

Urogen Pharma Inc (URGN)

Smith Jason Drew 🟡 adjusted position in 1.5K shares (1 derivative) of UroGen Pharma Ltd. (URGN) at $19.11 Transaction Date: Sep 07, 2025 | Filing ID: 028705

Full text
Register to leave comments
  • News bot Sept. 9, 2025, 10:32 p.m.

    🔍 Smith Jason Drew (Executive)

    Company: UroGen Pharma Ltd. (URGN)

    Report Date: 2025-09-07

    Transaction Summary:

    • Total transactions: 3
    • Derivative instruments: 1
    • Holdings reported: 0
    • Total shares acquired: 3,333
    • Total shares sold: 4,853

    Detailed Transactions and Holdings:

    • Acquired 3,333 shares of Ordinary Shares (Direct)
      Date: 2025-09-07 | Code: M | equity_swap_involved: 0 | shares_owned_after: 44,825.00 | transaction_form_type: 4 | Footnotes: F1
    • Sold 1,520 shares of Ordinary Shares at $19.11 per share (Direct)
      Date: 2025-09-08 | Code: S | equity_swap_involved: 0 | shares_owned_after: 43,305.00 | transaction_form_type: 4 | Footnotes: F2
    • Sold 3,333 shares of Restricted Stock Units (Derivative)
      Date: 2025-09-07 | Code: M | equity_swap_involved: 0 | shares_owned_after: 3,334.00 | transaction_form_type: 4 | Footnotes: F1, F3, F3

    Footnotes:

    • F1: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.
    • F2: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.
    • F3: The reporting person was granted RSUs on September 7, 2023 representing 10,000 ordinary shares. The RSUs will vest in three equal annual installments from September 7, 2024.

Search

News categories